New test helps evaluate cancer drug's merit

(HealthDay) -- A new genetic test to help doctors determine if the drug Erbitux would be an effective treatment for certain colorectal cancer patients has been approved by the U.S. Food and Drug Administration.

The KRAS RGQ PCR kit checks for the presence of a certain mutation in the KRAS gene. About 40 percent of people with colon cancer are thought to have the mutation, which leaves Erbitux ineffective. The test is for people whose colorectal cancer has spread to other parts of the body, the FDA said in a news release.

The says more than 141,000 new cases of colon cancer were diagnosed last year in the United States, and nearly 50,000 people died of the disease.

Erbitux (cetuximab), co-marketed by Bristol-Myers Squibb and Eli Lilly, was first approved as a treatment in 2004.

The new diagnostic was developed by Qiagen Manchester Ltd., based in Manchester, England.

More information: Visit the FDA to learn more about this approval.

Related Stories

Researchers link genetic marker to rectal cancer treatment

date Jul 06, 2011

A team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can ...

Merck KGaA suffers setback on cancer drug

date Jul 05, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Too many americans skipping colon cancer screening

date Mar 02, 2012

(HealthDay) -- Approximately one in three U.S. adults between the ages of 50 and 75 who should be screened for colorectal cancer have not been, according to the American Society for Gastrointestinal Endoscopy.

Recommended for you

Spicy treatment the answer to aggressive cancer?

date 18 hours ago

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.